All In Biotech

Drug Trial Radar · NCT07153497

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

A Randomized Phase 2 Trial of Olutasidenib-Based Therapies in Patients With Newly Diagnosed IDH1-Mutant Myeloid Malignancies: A MyeloMATCH Substudy

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Nov 27, 2026

Primary completion

Apr 26, 2030

Study completion Apr 26, 2030

Sponsor

Sponsor type
NIH
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the IDH1 gene. Olutasidenib blocks the protein made by the mutated IDH1 gene. Blocking this protein may help keep cancer cells from growing. For patients with MDS, olutasidenib will be added to decitabine-cedazuridine (also called ASTX727). Decitabine is in a class of medications called hypomethylating agents and is the standard treatment for MDS. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. The cedazuridine makes it possible to take the decitabine by mouth. Adding olutasidenib to the usual treatment for MDS (ASTX727) may increase the likelihood of going into remission. For patients with AML, olutasidenib and ASTX727 will be combined with venetoclax, a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Adding olutasidenib to the usual treatment for AML (ASTX727 and venetoclax) may increase the likelihood of going into remission. For low risk MDS, the substudy tests whether giving olutasidenib alone helps improve blood counts.

Conditions

  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Decitabine and CedazuridineDrug

    Given PO

  • OlutasidenibDrug

    Given PO

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal residual disease (MRD)-negative complete response (CR) + CR with partial hematological recovery (CRh) + CR with incomplete bone marrow recovery (CRi) (Cohort A)Time frame: Up to 4 cycles post randomization (Cycles = 28 days)
  2. Rate of CR (Cohort B)Time frame: Up to 6 cycles post randomization (Cycles = 28 days)
  3. Rate of hematologic improvement (HI) (Cohort C)Time frame: Up to 6 cycles post randomization (Cycles = 28 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.